Digital Biomarkers & Digital Diagnostics

Health Advances was engaged by a wearable device manufacturer to inform its strategy in building a robust product offering to support pharma using digital measures in clinical trials. The team conducted primary research with industry stakeholders and deep secondary research to identify the most attractive indication areas for digital biomarkers and measures and determine what technology and services the company should build to establish a leading position in the biopharma clinical development market. Health Advances delivered a detailed strategic roadmap and tactical recommendations to the client to use in near-term planning initiatives.

A leading pharma company with growing portfolio of immunology drugs engaged Health Advances to assess opportunities for digital biomarkers that could add value in trials or in the clinic in six disease states: Atopic Dermatitis, Psoriasis, IBD, Crohn's Disease, Lupus and Psoriatic Arthritis. Our team leveraged a deep understanding of current approaches used for screening, diagnosis, treatment and management of patients with these conditions to identify the shortcomings of current approaches and opportunities for digital biomarkers to address these shortcomings. The resulting deliverable was a prioritized list of opportunities to consider in the near-term, including tactical considerations for successful execution and attractive partners to approach to access the required technologies for success.